Ayako Mitsuma1, Yasuki Ito2,3, Tomoya Shimokata1, Chie Tanaka4, Kay Uehara5, Goro Nakayama4, Hiroko Terasaki2, Yuichi Ando1. 1. Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan. 2. Department of Ophthalmology, Nagoya University Hospital, Nagoya, Japan. 3. Department of Ophthalmology, Fujita Health University School of Medicine, Aichi, Japan. 4. Department of Gastroenterological Surgery, Nagoya University Hospital, Nagoya, Japan. 5. Division of Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Abstract
BACKGROUND/AIM: Antiangiogenic chemotherapy is the backbone of the various anticancer therapies. To date no practical biomarker predicting their antitumor effects and toxicity has been reported. We aimed to determine the feasibility of direct retinal observation as a practical biomarker in antiangiogenic chemotherapy. PATIENTS AND METHODS: By direct retinal observation using a nonmydriatic retinal camera, we measured retinal microvessel diameters in 10 patients with colorectal cancer before and after intravenous infusion of bevacizumab and oxaliplatin. All patients also received oral capecitabine during their therapy. RESULTS: Retinal microvessel diameters were decreased from baseline temporarily by 14.5±6.5% after infusion of bevacizumab and oxaliplatin in five patients who responded to treatment and 8.8±6.2% in the other five patients (p=0.008). CONCLUSION: Measurement of retinal microvessel diameters by direct observation appears to be feasible in patients receiving systemic chemotherapy. The decrease of retinal microvessel diameters might indicate improved tumor response to treatment with bevacizumab-containing systemic chemotherapy. Copyright 2022, International Institute of Anticancer Research.
BACKGROUND/AIM: Antiangiogenic chemotherapy is the backbone of the various anticancer therapies. To date no practical biomarker predicting their antitumor effects and toxicity has been reported. We aimed to determine the feasibility of direct retinal observation as a practical biomarker in antiangiogenic chemotherapy. PATIENTS AND METHODS: By direct retinal observation using a nonmydriatic retinal camera, we measured retinal microvessel diameters in 10 patients with colorectal cancer before and after intravenous infusion of bevacizumab and oxaliplatin. All patients also received oral capecitabine during their therapy. RESULTS: Retinal microvessel diameters were decreased from baseline temporarily by 14.5±6.5% after infusion of bevacizumab and oxaliplatin in five patients who responded to treatment and 8.8±6.2% in the other five patients (p=0.008). CONCLUSION: Measurement of retinal microvessel diameters by direct observation appears to be feasible in patients receiving systemic chemotherapy. The decrease of retinal microvessel diameters might indicate improved tumor response to treatment with bevacizumab-containing systemic chemotherapy. Copyright 2022, International Institute of Anticancer Research.
Authors: Gerald Liew; Shweta Kaushik; Elena Rochtchina; Ava G Tan; Paul Mitchell; Jie Jin Wang Journal: Ophthalmology Date: 2006-07-07 Impact factor: 12.079
Authors: M Kamran Ikram; Redmer van Leeuwen; Johannes R Vingerling; Albert Hofman; Paulus T V M de Jong Journal: Ophthalmology Date: 2005-04 Impact factor: 12.079
Authors: Priti S Hegde; Adrian M Jubb; Dafeng Chen; Nicole F Li; Y Gloria Meng; Coen Bernaards; Rebecca Elliott; Stefan J Scherer; Daniel S Chen Journal: Clin Cancer Res Date: 2012-11-20 Impact factor: 12.531
Authors: Y Yamada; T Denda; M Gamoh; I Iwanaga; S Yuki; H Shimodaira; M Nakamura; T Yamaguchi; H Ohori; K Kobayashi; M Tsuda; Y Kobayashi; Y Miyamoto; M Kotake; K Shimada; A Sato; S Morita; S Takahashi; Y Komatsu; C Ishioka Journal: Ann Oncol Date: 2018-03-01 Impact factor: 32.976
Authors: Sam Kushner-Lenhoff; Kaitlin Kogachi; Melissa Mert; Zhongdi Chu; Anoush Shahidzadeh; Neal V Palejwala; Jeremy Wolfe; Sujit Itty; Kimberly A Drenser; Antonio Capone; Pravin U Dugel; Andrew A Moshfeghi; Hossein Ameri; Lauren P Daskivich; Ruikang K Wang; Amir H Kashani Journal: PLoS One Date: 2022-01-26 Impact factor: 3.240
Authors: Robyn J Tapp; Christopher G Owen; Sarah A Barman; Roshan A Welikala; Paul J Foster; Peter H Whincup; David P Strachan; Alicja R Rudnicka Journal: Hypertension Date: 2019-10-30 Impact factor: 10.190